Skip to main content

Market Overview

UPDATE: JP Morgan Raises PT on Vertex Pharmaceuticals on Phase 3 Trials


JP Morgan analyst Geoff Meacham published a report on Vertex Pharmaceuticals (NASDAQ: VRTX) that reiterated its Overweight rating and raised the price target from $82 to $86.

JP Morgan reported that, “Vertex's phase 3 strategy in F508del cystic fibrosis (CF) patients was recently communicated with two trials, TRAFFIC and TRANSPORT, launching soon. Surrounding this development, we spoke with a number of physicians and CFspecific researchers, as well as reviewed the literature. We came away more confident in the probability of success in phase 3, based on our feedback, and on an updated SOTP analysis and sensitivity for the value of the VX-809 combo in this population. Physicians we spoke to had a positive bias toward TRAFFIC / TRANSPORT, noting a +2-4% change in FEV1 would be “clinically meaningful” and would position the VX-809 / Kalydeco combo as a widely held standard of care.”

Shares of Vertex Pharmaceuticals closed at $51.37 on Monday

Latest Ratings for VRTX

Feb 2021BairdUpgradesNeutralOutperform
Feb 2021Piper SandlerMaintainsOverweight
Feb 2021BMO CapitalMaintainsOutperform

View More Analyst Ratings for VRTX
View the Latest Analyst Ratings


Related Articles (VRTX)

View Comments and Join the Discussion!

Posted-In: JP MorganAnalyst Color Price Target Analyst Ratings

Latest Ratings

NUVAMorgan StanleyMaintains65.0
NTRSMorgan StanleyMaintains131.0
NTRAMorgan StanleyMaintains140.0
MUMorgan StanleyMaintains105.0
MRVLMorgan StanleyMaintains49.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at